Published in Proc Natl Acad Sci U S A on December 02, 2004
Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci U S A (2005) 3.40
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
Drosophila models of neurodegenerative diseases. Annu Rev Pathol (2009) 1.67
Parkinson's disease: insights from pathways. Hum Mol Genet (2010) 1.52
In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp Neurol (2007) 1.51
Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc Natl Acad Sci U S A (2005) 1.48
Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol (2006) 1.47
Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease? Front Neuroanat (2016) 1.39
Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest (2008) 1.38
Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem (2011) 1.33
Applying Hsp104 to protein-misfolding disorders. Biochem Cell Biol (2010) 1.18
Parkin promotes intracellular Abeta1-42 clearance. Hum Mol Genet (2009) 1.18
Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord (2012) 1.17
Parkinson's disease: gene therapies. Cold Spring Harb Perspect Med (2012) 1.13
MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol Dis (2007) 1.09
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats. Brain (2013) 1.07
Value of genetic models in understanding the cause and mechanisms of Parkinson's disease. Curr Neurol Neurosci Rep (2008) 1.06
Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. Neurobiol Dis (2010) 1.02
Methamphetamine oxidatively damages parkin and decreases the activity of 26S proteasome in vivo. J Neurochem (2011) 1.00
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS One (2009) 0.95
Parkinson's disease: a rethink of rodent models. Exp Brain Res (2006) 0.95
Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model. Mol Neurodegener (2010) 0.95
Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration. J Clin Invest (2015) 0.95
Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. PLoS One (2012) 0.95
Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function. J Neurosci Res (2010) 0.93
HIV-1 Tat interacts with and regulates the localization and processing of amyloid precursor protein. PLoS One (2013) 0.92
Restriction of trophic factors and nutrients induces PARKIN expression. Neurogenetics (2011) 0.92
Antioxidant gene therapy against neuronal cell death. Pharmacol Ther (2013) 0.92
Combined kinase inhibition modulates parkin inactivation. Hum Mol Genet (2008) 0.92
α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92
Role of the ubiquitin proteasome system in Parkinson's disease. BMC Biochem (2007) 0.91
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
Neuroprotective effects of a variety of pomegranate juice extracts against MPTP-induced cytotoxicity and oxidative stress in human primary neurons. Oxid Med Cell Longev (2013) 0.90
Clinical applications involving CNS gene transfer. Adv Genet (2014) 0.89
Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clin Geriatr Med (2010) 0.88
Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. Front Aging Neurosci (2010) 0.88
Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD. Acta Neuropathol (2014) 0.85
Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model. Neurosci Lett (2006) 0.84
Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease. Neurobiol Dis (2013) 0.84
Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses. Neurotherapeutics (2007) 0.84
Inhibition of store-operated calcium entry attenuates MPP(+)-induced oxidative stress via preservation of mitochondrial function in PC12 cells: involvement of Homer1a. PLoS One (2013) 0.83
Gene therapy for Parkinson's disease. Parkinsons Dis (2012) 0.83
Gene-based therapies in Parkinson's disease. Neurotherapeutics (2014) 0.83
Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease. Cell Death Dis (2014) 0.82
Optimization of Tet1 ligand density in HPMA-co-oligolysine copolymers for targeted neuronal gene delivery. Biomaterials (2013) 0.82
Targeting the progression of Parkinson's disease. Curr Neuropharmacol (2009) 0.82
Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology. Behav Neurol (2015) 0.82
Protective effects of SKF-96365, a non-specific inhibitor of SOCE, against MPP+-induced cytotoxicity in PC12 cells: potential role of Homer1. PLoS One (2013) 0.82
Controlled and localized genetic manipulation in the brain. J Cell Mol Med (2006) 0.81
Highly efficient generation of transgenic sheep by lentivirus accompanying the alteration of methylation status. PLoS One (2013) 0.81
Molecular aspects of dopaminergic neurodegeneration: gene-environment interaction in parkin dysfunction. Int J Environ Res Public Health (2011) 0.81
Behavioral and neurotransmitter abnormalities in mice deficient for Parkin, DJ-1 and superoxide dismutase. PLoS One (2013) 0.81
Morphologic and functional changes in the unilateral 6-hydroxydopamine lesion rat model for Parkinson's disease discerned with microSPECT and quantitative MRI. MAGMA (2010) 0.80
Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinson's disease. Mol Neurodegener (2015) 0.80
Versatile somatic gene transfer for modeling neurodegenerative diseases. Neurotox Res (2009) 0.80
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci (2016) 0.80
Gene therapy: a viable therapeutic strategy for Parkinson's disease? J Neurol (2010) 0.80
Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity. Exp Neurol (2013) 0.79
Advances in gene therapy for movement disorders. Neurotherapeutics (2008) 0.79
Brevetoxin-induced neural insult in the retrosplenial cortex of mouse brain. Inhal Toxicol (2006) 0.78
Both creatine and its product phosphocreatine reduce oxidative stress and afford neuroprotection in an in vitro Parkinson's model. ASN Neuro (2014) 0.78
Pathologic and therapeutic implications for the cell biology of parkin. Mol Cell Neurosci (2015) 0.78
Human gene therapy and imaging in neurological diseases. Eur J Nucl Med Mol Imaging (2005) 0.77
Genetic rat models of Parkinson's disease. Parkinsons Dis (2012) 0.77
Generation of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug Screening. PLoS One (2015) 0.77
How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease? J Neurochem (2016) 0.76
The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases. Front Psychiatry (2010) 0.76
Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration. Mol Neurodegener (2015) 0.75
Understanding and treating neurodegeneration: insights from the flies. Age (Dordr) (2005) 0.75
Cell-permeable parkin proteins suppress Parkinson disease-associated phenotypes in cultured cells and animals. PLoS One (2014) 0.75
Reverse genetics for proteomics: from proteomic discovery to scientific content. J Neural Transm (Vienna) (2006) 0.75
Gene therapy targeting mitochondrial pathway in Parkinson's disease. J Neural Transm (Vienna) (2016) 0.75
Tectorigenin attenuates the MPP(+)-induced SH-SY5Y cell damage, indicating a potential beneficial role in Parkinson's disease by oxidative stress inhibition. Exp Ther Med (2017) 0.75
Viral vectors as a tool to model and treat Parkinson's disease. Wien Klin Wochenschr (2006) 0.75
Animal models of α-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet (2000) 7.83
Molecular pathways of neurodegeneration in Parkinson's disease. Science (2003) 7.55
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001) 4.48
An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell (2001) 4.41
Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med (2001) 4.22
Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem (2000) 3.86
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet (2003) 3.51
Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol (1997) 3.37
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci (2002) 3.12
Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry (2001) 2.96
alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A (2002) 2.81
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron (2002) 2.65
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron (2003) 2.49
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest (2002) 2.47
Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol (2000) 2.47
Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry (2002) 2.29
CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem (2003) 2.27
Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron (1999) 2.25
Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron (2003) 2.12
Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 1.92
Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol (1999) 1.86
Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther (2000) 1.81
Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther (2002) 1.63
Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem (2003) 1.60
Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology (1994) 1.46
Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci (2003) 1.37
An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord (2000) 1.29
Pathways to Parkinsonism. Neuron (2003) 1.26
Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology (2001) 1.15
Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci Lett (2003) 1.08
Parkin's substrates and the pathways leading to neuronal damage. Neuromolecular Med (2003) 1.03
Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol (2003) 1.00
Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. J Neurol (2003) 0.96
Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci (2003) 0.96
Parkin suppresses wild-type alpha-synuclein-induced toxicity in SHSY-5Y cells. Biochem Biophys Res Commun (2003) 0.93
Silver staining as a tool for neurotoxic assessment. NIDA Res Monogr (1993) 0.88
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2002) 9.90
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
APP processing and synaptic function. Neuron (2003) 8.37
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet (2005) 7.66
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron (2006) 6.76
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
The role of presenilin cofactors in the gamma-secretase complex. Nature (2003) 5.03
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med (2013) 4.11
A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol (2006) 4.05
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Nutrient control of gene expression in Drosophila: microarray analysis of starvation and sugar-dependent response. EMBO J (2002) 3.58
Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet (2009) 3.56
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet (2003) 3.51
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med (2006) 2.93
A versatile tool for conditional gene expression and knockdown. Nat Methods (2006) 2.92
Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med (2005) 2.80
Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet (2004) 2.75
GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry (2007) 2.71
LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci (2011) 2.52
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest (2002) 2.47
Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem (2003) 2.42
Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron (2008) 2.40
Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci (2012) 2.35
Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet (2006) 2.34
Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings. Ann Neurol (2012) 2.33
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem (2012) 2.31
TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol (2009) 2.30
Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet (2003) 2.26
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet (2006) 2.24
Opposing effects of dietary protein and sugar regulate a transcriptional target of Drosophila insulin-like peptide signaling. Cell Metab (2008) 2.22
What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev (2011) 2.21
Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet (2010) 2.21
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am J Hum Genet (2002) 2.17
Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet (2007) 2.17
Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther (2008) 2.14
Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem (2004) 2.11
Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet (2006) 2.09
Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med (2012) 2.02
Autosomal recessive cortical myoclonic tremor and epilepsy: association with a mutation in the potassium channel associated gene CNTN2. Brain (2013) 2.02
GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One (2007) 1.99
Lentiviral-mediated RNA interference. Hum Gene Ther (2002) 1.99
A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci U S A (2003) 1.92
Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. J Biol Chem (2010) 1.92
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep (2002) 1.91
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol (2004) 1.90
Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol (2007) 1.89
Cytoplasmic localization and proteasomal degradation of N-terminally cleaved form of PINK1. Neurosci Lett (2007) 1.88
SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet (2010) 1.85
Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain (2008) 1.84
The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet (2003) 1.83
Hereditary spastic paraplegias: an update. Curr Opin Neurol (2007) 1.83
Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies. Brain (2003) 1.82
Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol (2008) 1.81
Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. PLoS Genet (2009) 1.81
Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol (2013) 1.79
Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. Am J Hum Genet (2008) 1.79
Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem (2002) 1.77
A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol (2010) 1.77
G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol (2013) 1.77
Mutations in KCND3 cause spinocerebellar ataxia type 22. Ann Neurol (2012) 1.76
Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain (2007) 1.76
Atlastin1 mutations are frequent in young-onset autosomal dominant spastic paraplegia. Arch Neurol (2004) 1.72
Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients. Arch Neurol (2007) 1.72
GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther (2005) 1.72
Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem (2002) 1.71
Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia. Am J Hum Genet (2012) 1.71
Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. Mol Biol Cell (2007) 1.69
Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry (2006) 1.69
Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat (2007) 1.69
PARK6-linked parkinsonism occurs in several European families. Ann Neurol (2002) 1.68
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet (2012) 1.68
Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain (2003) 1.68
Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet (2010) 1.67
Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines. J Neurosci (2006) 1.66
Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther (2008) 1.66
Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis (2010) 1.65
Parkinson's disease patients show reduced cortical-subcortical sensorimotor connectivity. Mov Disord (2012) 1.64
Activity-dependent proteolytic cleavage of neuroligin-1. Neuron (2012) 1.64
LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci (2009) 1.64
Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci (2005) 1.63
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain (2008) 1.61
Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol (2003) 1.59
The Kruppel-associated box repressor domain can trigger de novo promoter methylation during mouse early embryogenesis. J Biol Chem (2007) 1.59
Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations. Mov Disord (2007) 1.58
Brain white matter oedema due to ClC-2 chloride channel deficiency: an observational analytical study. Lancet Neurol (2013) 1.58
Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. EMBO J (2002) 1.57
Complicated forms of autosomal dominant hereditary spastic paraplegia are frequent in SPG10. Hum Mutat (2009) 1.57
Heterozygous OPA1 mutations in Behr syndrome. Brain (2010) 1.57